Description

The present study purposed to observe the response of comorbidities of temporomandibular disorders (TMD) including migraine and cervical dysfunction after painful TMD treatment. Migraine disproportionately affects women of reproductive age, and is associated with self-directed violence (SDV) which confers substantial risk for suicides. Mental health disorders (MHD) and substance use disorders (SUD) are higher among persons with migraines. However, there's limited information on the influence of these conditions on SDV among women. We evaluated the interplay of MHD and SUD on the relation of migraine with SDV among US women.

Migraine is a widespread and debilitating neurological condition affecting more than a billion people worldwide. Thus, more effective migraine therapies are highly needed. In the last decade, two endogenous neuropeptides, calcitonin gene-related peptide (CGRP) and pituitary acetylate cyclase-activating peptide (PACAP), were identified to be implicated in migraine. Recently, introduction of monoclonal antibodies (mAbs) blocking the CGRP is the most important advance in migraine therapy for decades. However, 40% of patients are unresponsive to these new drugs. There are several treatments to control migraine pain and symptoms, and the most common pharmaceutical form used is oral tablets. Oral treatment during acute migraine attacks is not fully effective because of its associated symptoms, such as nausea and vomiting, and oral administration of actives also limits bioavailability. Transdermal formulations are a promising alternative for the administration of these actives, as they can considerably improve the bioavailability and efficacy of the treatment, without the inconvenience of invasive treatments. Thus, this article reviews transdermal delivery systems for migraine, emphasizing advantages, as promising technological strategies for effective, comfortable, and strong adhesion promoters to migraine treatment, presenting studies available in the area, as well as the lack of drugs available on the market for transdermal delivery.

Kindly submit your manuscript through https://www.imedpub.com/submissions/reproductive-endocrinology-infertility.html

With Regards
Sanjeev

Journal Coordinator
Journal of Reproductive Endocrinology & Infertility